Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-FAPI-46 PET for Staging Transthyretin Cardiac Amyloidosis
NCT07549841Phase 2Recruiting
- Sponsor
- CHU de Nantes
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga FAPI-46 in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by CHU de Nantes. Started Sep 2026; status: recruiting.
02
Drugs
68Ga FAPI-46
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07549841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549841.